Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD

Abstract

Objective: This study examined cardiovascular safety of concomitant use of long-acting stimulants (LAS) and atypical antipsychotics (AAP) in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Method: The study used 2004-2007 IMS LifeLink™ claims data involving 6- to 16-year-old children with ADHD and at least one LAS prescription from July 2004 to December 2006. Time-dependent Cox regression analysis was performed to evaluate the risk of cardiovascular disease (CVD) events due to concomitant use of LAS and AAP. Results: The analytical cohort consisted of 37,903 children: 538 (1.9%) used LAS and AAP concurrently and the rest used LAS monotherapy. Time-dependent Cox regression analysis revealed no difference in CVD risk among concomitant users of LAS and AAP (hazard ratio = 1.19; 95% confidence interval = [0.60, 2.53]) when compared with users of LAS monotherapy. Conclusion: Concomitant use of LAS and AAP was not associated with risk of CVD events in ADHD patients when compared with LAS monotherapy.

Keywords

ADD/ADHD stimulants atypical antipsychotics concomitant use polypharmacy cardiovascular safety risk

Get full access to this article

View all access options for this article.

References

Abou-Setta

A. M.

Mousavi

S. S.

Spooner

Schouten

J. R.

Pasichnyk

Armijo-Olivo

. . . Hartling

(2012). First-generation versus second-generation antipsychotics in adults: Comparative effectiveness [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US). Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK107254/

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601.

Andersen

Newman

J. F.

(1973). Societal and individual determinants of medical care utilization in the United States. The Milbank Memorial Fund Quarterly: Health and Society, 51, 95-124.

Bali

Kamble

P. S.

Aparasu

R. R.

(2015). Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder. Journal of Managed Care & Specialty Pharmacy, 21, 486-498.

Bloom

Cohen

R. A.

Freeman

(2010). Summary health statistics for U.S. children: National Health Interview Survey, 2009. Vital and Health Statistics, 10(247), 1-82.

Cascade

Kalali

A. H.

Weisler

R. H.

(2008). Short-acting versus long-acting medications for the treatment of ADHD. Psychiatry, 5(8), 24-27.

Chacko

Newcorn

J. H.

Feirsen

Uderman

J. Z.

(2010). Improving medication adherence in chronic pediatric health conditions: A focus on ADHD in youth. Current Pharmaceutical Design, 16, 2416-2423.

Chen

C.-Y. [Chih-Ying]

Gerhard

Winterstein

A. G.

(2009). Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19, 187-195.

Chen

C.-Y. [Chuan-Yu]

Yeh

H.-H.

Chen

K.-H.

Chang

I. S.

E. C.-H.

Lin

K.-M.

(2011). Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21, 265-273.

10.

Christensen

Sasané

Hodgkins

Harley

Tetali

(2010). Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: Retrospective claims-based analysis of a managed care population. Current Medical Research and Opinion, 26, 977-989.

11.

Comer

J. S.

Olfson

Mojtabai

(2010). National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. Journal of the American Academy of Child & Adolescent Psychiatry, 49, 1001-1010.

12.

Cooper

W. O.

Habel

L. A.

Sox

C. M.

Chan

K. A.

Arbogast

P. G.

Cheetham

T. C.

Ray

W. A.

(2011). ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine, 365, 1896-1904.

13.

Cooper

W. O.

Hickson

G. B.

Fuchs

Arbogast

P. G.

Ray

W. A.

(2004). New users of antipsychotic medications among children enrolled in TennCare. Archives of Pediatrics & Adolescent Medicine, 158, 753-759.

14.

Correll

C. U.

Carlson

H. E.

(2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 771-791.

15.

Correll

C. U.

Penzner

J. B.

Parikh

U. H.

Mughal

Javed

Carbon

Malhotra

A. K.

(2006). Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 15, 177-206.

16.

Crystal

Olfson

Huang

Pincus

Gerhard

(2009). Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Affairs, 28, w770-w781.

17.

Daniels

S. R.

Pratt

C. A.

Hayman

L. L.

(2011). Reduction of risk for cardiovascular disease in children and adolescents. Circulation, 124, 1673-1686.

18.

Donner

Michaels

M. A.

Ambrosini

P. J.

(2007). Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biological Psychiatry, 61, 706-712.

19.

Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents & National Heart, Lung, and Blood Institute. (2011). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics, 128(Suppl. 5), S213-S256.

20.

Findling

R. L.

Short

E. J.

Manos

M. J.

(2001). Short-term cardiovascular effects of methylphenidate and adderall. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 525-529.

21.

Gelperin

Brinker

Avigan

(2006). MedWatch reporting of death, sudden death, and cardiovascular events in association with stimulants used in the treatment of ADHD over a recent 5-year period. Rockville, MD: U.S. Food and Drug Administration.

22.

Gugger

J. J.

(2011). Antipsychotic pharmacotherapy and orthostatic hypotension: Identification and management. CNS Drugs, 25, 659-671.

23.

IMS LifeLink. (n.d.). IMS LifeLink health plan claims database: Overview and study design issues. Retrieved from http://www.uams.edu/TRI/hsrcore/Lifelink_Health_Plan_Claims_Data_DesignIssues_wcost_April2010[1].pdf

24.

Jerrell

J. M.

McIntyre

R. S.

(2008). Adverse events in children and adolescents treated with antipsychotic medications. Human Psychopharmacology, 23, 283-290.

25.

Kotzan

J. A.

Maclean

Wade

Martin

B. C.

Iami

Tadlock

Gottlieb

(2002). Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. Clinical Therapeutics, 24, 237-248.

26.

Lawson

K. A.

Johnsrud

Hodgkins

Sasané

Crismon

M. L.

(2012). Utilization patterns of stimulants in ADHD in the Medicaid population: A retrospective analysis of data from the Texas Medicaid program. Clinical Therapeutics, 34, 944-956.

27.

Maglione

Maher

A. R.

Wang

Shanman

Shekelle

P. G.

. . . Perry

(2011). Off-label use of atypical antipsychotics: An update. Rockville, MD: Agency for Healthcare Research and Quality. Retrieved from http://www.effectivehealthcare.ahrq.gov/reports/final.cfm

28.

Martin

Van Hoof

Stubbe

Sherwin

Scahill

(2003). Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services, 54, 72-77.

29.

Matza

L. S.

Paramore

Prasad

(2005). A review of the economic burden of ADHD. Cost Effectiveness and Resource Allocation, 3, Article 5.

30.

Mazza

D’Ascenzo

Davico

Biondi-Zoccai

Frati

Romagnoli

. . . Gaita

(2013). Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: A meta-analysis of observational studies. International Journal of Cardiology, 168, 4320-4321.

31.

McIntyre

R. S.

Jerrell

J. M.

(2008). Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics & Adolescent Medicine, 162, 929-935.

32.

Michelsen

J. W.

Meyer

J. M.

(2007). Cardiovascular effects of antipsychotics. Expert Review of Neurotherapeutics, 7, 829-839.

33.

Mick

McManus

D. D.

Goldberg

R. J.

(2013). Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. European Neuropsychopharmacology, 23, 534-541.

34.

Miller

(2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. Current Neuropharmacology, 7, 302-314.

35.

Mojtabai

Olfson

(2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67, 26-36.

36.

National Institute of Mental Health. (2008). Attention deficit hyperactivity disorder (ADHD). Retrieved from http://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-easy-to-read/adhd-trifold-new_150044.pdf

37.

Nissen

S. E.

(2006). ADHD drugs and cardiovascular risk. New England Journal of Medicine, 354, 1445-1448.

38.

Olfson

Blanco

Liu

S. M.

Wang

Correll

C. U.

(2012). National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry, 69, 1247-1256.

39.

Palli

S. R.

Kamble

P. S.

Chen

Aparasu

R. R.

(2012). Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 22, 139-148.

40.

Penzner

J. B.

Dudas

Saito

Olshanskiy

Parikh

U. H.

Kapoor

. . . Correll

C. U.

(2009). Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. Journal of Child and Adolescent Psychopharmacology, 19, 563-573.

41.

Pliszka

S. R.

(2003). Psychiatric comorbidities in children with attention deficit hyperactivity disorder. Pediatric Drugs, 5, 741-750.

42.

Radigan

Lannon

Roohan

Gesten

(2005). Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population. Journal of Child and Adolescent Psychopharmacology, 15, 44-56.

43.

Samuels

J. A.

Franco

Wan

Sorof

J. M.

(2006). Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: A double-blind, randomized, cross-over trial. Pediatric Nephrology, 21, 92-95.

44.

Sanchez

R. J.

Crismon

M. L.

Barner

J. C.

Bettinger

Wilson

J. P.

(2005). Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 25, 909-917.

45.

Schelleman

Bilker

W. B.

Strom

B. L.

Kimmel

S. E.

Newcomb

Guevara

J. P.

. . . Hennessy

(2011). Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics, 127, 1102-1110.

46.

Seida

J. C.

Schouten

J. R.

Boylan

Newton

A. S.

Mousavi

S. S.

Beaith

. . . Carrey

(2012). Antipsychotics for children and young adults: A comparative effectiveness review. Pediatrics, 129, e771-e784.

47.

Stahl

S. M.

(2010). Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 71, 12-13.

48.

Stowe

C. D.

Gardner

S. F.

Gist

C. C.

Schulz

E. G.

Wells

T. G.

(2002). 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Annals of Pharmacotherapy, 36, 1142-1149.

49.

U.S. Food and Drug Administration. (n.d.). Alert for health professionals: Adderall and adderall XR (amphetamine). Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111441.htm

50.

U.S. Food and Drug Administration. (2000). Psychopharma-cological Drugs Advisory Committee: Briefing document for Zeldox® capsules (Ziprasidone HCl). Retrieved from http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf

51.

Volkow

N. D.

Wang

G. J.

Fowler

J. S.

Molina

P. E.

Logan

Gatley

S. J.

. . . Swanson

J. M.

(2003). Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology, 166, 264-270.

52.

Waxmonsky

(2003). Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Current Opinion in Pediatrics, 15, 476-482.

53.

Weisler

R. H.

Biederman

Spencer

T. J.

Wilens

T. E.

(2005). Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums, 10(12, Suppl. 20), 35-43.

54.

Weiss

Panagiotopoulos

Giles

Gibbins

Kuzeljevic

Davidson

Harrison

(2009). A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. Journal of Child and Adolescent Psychopharmacology, 19, 575-582.

55.

Wilens

T. E.

Hammerness

P. G.

Biederman

Kwon

Spencer

T. J.

Clark

. . . Moore

(2005). Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 66, 253-259.

56.

Willcutt

E. G.

(2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 9, 490-499.

57.

Winterstein

A. G.

(2013). Cardiovascular safety of stimulants in children: Findings from recent population-based cohort studies. Current Psychiatry Reports, 15(8), Article 379.

58.

Winterstein

A. G.

Gerhard

Shuster

Johnson

Zito

J. M.

Saidi

(2007). Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 120, e1494-e1501.

59.

Winterstein

A. G.

Gerhard

Shuster

Saidi

(2009). Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics, 124, e75-e80.

60.

Winterstein

A. G.

Gerhard

Shuster

Zito

Johnson

Liu

Saidi

(2008). Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Annals of Pharmacotherapy, 42, 24-31.

61.

Wolraich

Brown

R. T.

DuPaul

Earls

Feldman

H. M.

Visser

(2011). ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128, 1007-1022.

62.

Yanofski

(2010). The dopamine dilemma: Using stimulants and antipsychotics concurrently. Psychiatry, 7(6), 18-23.

63.

Zito

J. M.

Derivan

A. T.

Kratochvil

C. J.

Safer

D. J.

Fegert

J. M.

Greenhill

L. L.

(2008). Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child & Adolescent Psychiatry & Mental Health, 2(1), Article 24.

64.

Zito

J. M.

Safer

D. J.

DosReis

Magder

L. S.

Gardner

J. F.

Zarin

D. A.

(1999). Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Archives of Pediatrics & Adolescent Medicine, 153, 1257-1263.